{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-05T02:01:09.943Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-05. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-05. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-05, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"VCYT\",\n  \"company\": \"Veracyte, Inc.\",\n  \"investigation_summary\": \"Veracyte presents a well-functioning diagnostics company with strong fundamentals and multiple positive catalysts — landmark Phase III ASCO data (OPTIMA for Prosigna, ENZAMET for Decipher Prostate), commercial US launch of Prosigna, and Medicare coverage secured for TrueMRD. However, the investigation trigger referencing insider open-market P/S clustering does not hold up under scrutiny: all 30 recent Form 4 filings are routine — RSU vesting at $0 strike (code A), tax-withholding sells (code F), or pre-scheduled Rule 10b5-1 plan sales (code S). Zero true discretionary open-market purchases from any insider. The stock is also near 52-week high, RSI=74.4 (overbought), and forward P/E of ~26x with EV/EBITDA of ~34x represents full valuation in a high-quality but richly priced name.\",\n  \"verdict\": \"range_bound_or_income\",\n  \"confidence_in_data\": 5,\n  \"structure_hints\": [\n    \"cc\",\n    \"strangle\"\n  ],\n  \"business_snapshot\": \"Veracyte is a $4B market cap diagnostics company offering genomic cancer tests across thyroid (Afirma), prostate (Decipher Prostate), bladder (Decipher Bladder), and breast (Prosigna) cancers, primarily via CLIA labs in the US. The business model generates strong 73% gross margins with testing revenue of ~$135M in Q1 2026 alone, growing double-digits across all major tests. Decipher Prostate is the dominant driver; Prosigna is now launching commercially as an LDT in the US after landmark Phase III OPTIMA data at ASCO 2026 demonstrated practice-changing utility to identify high-risk breast cancer patients who can safely avoid chemotherapy. The company had $439M cash and minimal debt at Q1 2026, generating positive operating income ($22.6M) for the first time on a scaled basis with improving profitability trajectory.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [],\n      \"insider_open_market_total_usd_90d\": 0,\n      \"distinct_insider_buyers_90d\": 0,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": null\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-08-05\",\n      \"recent_eps_surprise_pattern\": \"Q1 2026: EPS $0.52 actual vs $0.33 est (+56% surprise); Q4 2025: $0.53 actual vs $0.41 est (+30%); Q3 2025: $0.51 actual vs $0.32 est (+60%) — four consecutive earnings beats with consistent positive surprises\",\n      \"guidance_raise_in_last_90d\": true,\n      \"named_catalysts\": [\n        {\n          \"type\": \"product\",\n          \"description\": \"Prosigna US commercial launch as LDT following landmark OPTIMA Phase III trial (ASCO 2026) showing Prosigna-guided decisions can safely spare high-risk breast cancer patients from chemotherapy — practice-changing evidence with major reimbursement implications\",\n          \"date_or_window\": \"June 1, 2026 announced; commercial rollout ongoing\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/landmark-optima-trial-delivers-practice-191500912.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"ENZAMET Phase III trial at ASCO 2026: Decipher Prostate test identified prostate cancer patients who benefit from adding chemotherapy in metastatic setting, expanding clinical utility and addressable market\",\n          \"date_or_window\": \"May 30, 2026 presented at ASCO\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/enzamet-trial-shows-veracytes-decipher-120000559.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"Medicare coverage secured for TrueMRD monitoring test in muscle-invasive bladder cancer, enabling commercial launch of MRD detection platform with significant reimbursement pathway\",\n          \"date_or_window\": \"May 15, 2026 announced\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/veracyte-secures-medicare-coverage-truemrd-130000975.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"earnings\",\n          \"description\": \"Q2 2026 earnings with strong Q1 beat (+56% EPS surprise) setting high bar; ongoing double-digit revenue growth trajectory\",\n          \"date_or_window\": \"August 5, 2026\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/markets/stocks/articles/veracyte-vcyt-beats-q1-earnings-003013408.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": 26.27,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": 34.4,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": 2.6,\n      \"narrative\": \"Trading at 52-week high with forward P/E ~26x and EV/EBITDA ~34x — premium multiples reflecting strong growth but no mispricing discount vs intrinsic value. The company has turned profitable and is FCF positive, though FCF yield of only ~2.6% doesn't support deep undervaluation. Stock up 65%+ over the past year driven by known catalysts (ASCO data).\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": null,\n      \"net_debt_to_ebitda\": -10.7,\n      \"balance_sheet_grade\": \"A\"\n    },\n    \"technical\": {\n      \"above_50dma\": true,\n      \"above_200dma\": true,\n      \"rsi_14\": 74.4,\n      \"macd_recent_bullish_cross\": false,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 49.94,\n    \"ytd_return_pct\": 85.1,\n    \"from_52w_high_pct\": 1.5\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-02-26\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1384101/000138410126000010/vcyt-20251231.htm\",\n      \"key_takeaways\": [\n        \"FY2025 revenue ~$542M, up 21.5% YoY; strong Afirma and Decipher test volume growth; gross margin 73%; turned profitable with positive operating income; $439M cash, minimal debt; no going concern issues; disclosed Medicare/UnitedHealthcare as top two payers representing 47%+ of Q1 2026 revenue; Veracyte SAS deconsolidated Aug 2025\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-05-06\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1384101/000138410126000031/vcyt-20260331.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026 revenue $139M (+21.5% YoY); EPS $0.52 actual vs $0.33 est (+56%); testing revenue $135M (+26% YoY driven by Decipher and Afirma volume growth); gross profit $101M (73% margin); operating income $22.6M; cash $439M with minimal debt; RSU stock compensation expense $12.8M — strong quarter across all metrics\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-05-05\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1384101/000138410126000029/vcyt-20260505.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026 earnings press release; excellent start to year with double-digit revenue and test volume growth, improved profitability\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-06-18\",\n      \"2026-07-17\",\n      \"2026-09-18\"\n    ],\n    \"iv_summary\": \"IV data unavailable from options_chain — the chain returned empty (no strikes populated). Crude flow shows call-biased activity (9 calls vs 2 puts; put/call ratio 0.22) with net directional bias bullish at modest notional ($1,675 call / $830 put). Top open interest: 55 strike calls (16 contracts OI), 35 strike puts (12 contracts OI). Stock near all-time high reduces cheap premium for CSP writers but creates decent covered-call harvest opportunity.\",\n    \"notable_skew_or_flow\": \"Modest bullish flow at low notional; no whale blocks. The elevated stock price (~10% from 52w high) means ATM IV is likely in the 40-50 range — enough to generate meaningful CC premium but not exceptional. The August earnings (Aug 5) will be a natural covered-call expiry window.\"\n  },\n  \"competitive_landscape\": \"Veracyte competes against large liquid biopsy/platform plays like Exact Sciences (EXAS), Guardant Health (GH), and Natera (NTRA). Key differentiators: Decipher Prostate has strong clinical guideline inclusion for prostate cancer; Afirma is the established standard in thyroid nodule assessment. The space is highly competitive with well-funded players, but Veracyte's specific focus on urologic/genitourinary and thyroid oncology creates defensible niches rather than head-to-head competition across all tests.\",\n  \"key_risks\": [\n    \"Stock at 52-week high, RSI overbought (74.4) — elevated pullback risk\",\n    \"No actual open-market insider purchases despite the investigation trigger; Form 4 cluster was routine vesting/selling only\",\n    \"Forward P/E of ~26x is full valuation with limited margin of safety for error\",\n    \"Revenue concentration: Medicare + UnitedHealthcare = 47% of Q1 revenue — payer leverage risk\",\n    \"Highly competitive liquid biopsy / genomic diagnostics space with better-funded rivals\",\n    \"Single-source reagent suppliers create supply chain vulnerability explicitly disclosed in filings\",\n    \"FDA regulatory risk as LDT framework evolves under new administration\"\n  ],\n  \"what_the_market_might_be_missing\": \"Nothing material. The ASCO Phase III data is already priced in (stock +65% YoY, at 52w high). Multiple Form 4 transactions gave a misleading signal of insider buying but were all routine — RSU vesting and tax withholding sales. TrueMRD launch could be an underappreciated revenue driver if MRD surveillance becomes standard-of-care in bladder cancer, but this is speculative and already partially priced.\",\n  \"anti_signals_present\": [\n    \"low_liquidity\",\n    \"pump_signals\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"Q1 2026 10-Q\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1384101/000138410126000031/vcyt-20260331.htm\"\n    },\n    {\n      \"label\": \"FY2025 10-K\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1384101/000138410126000010/vcyt-20251231.htm\"\n    },\n    {\n      \"label\": \"Q1 2026 Earnings 8-K\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1384101/000138410126000029/vcyt-20260505.htm\"\n    },\n    {\n      \"label\": \"OPTIMA ASCO Trial Results (Prosigna)\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/landmark-optima-trial-delivers-practice-191500912.html\"\n    },\n    {\n      \"label\": \"ENZAMET Trial Results (Decipher Prostate)\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/enzamet-trial-shows-veracytes-decipher-120000559.html\"\n    },\n    {\n      \"label\": \"Prosigna US Commercial Launch\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/veracyte-announces-commercial-launch-prosigna-113000653.html\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-05T02:01:57.587Z",
      "raw_content": "<think>The dossier is for VCYT (Veracyte, Inc.).\nScout verdict: `range_bound_or_income`.\nScoring inputs:\n- Smart Money: 0 pts (no insider purchases, no 13F, etc.)\n- Options Flow: 0 pts (no whale blocks, low notional, no IV data)\n- Catalyst: 10 pts (earnings within 90 days, last 4 quarters EPS surprise > 0%) + 5 pts (guidance raise) = 15 pts. (Cap at 25, but let's stick to what's there. Actually, catalyst says 10 for earnings + 4 consecutive beats. I'll give 10 for earnings + 5 for guidance raise = 15. Wait, rubric says 10 for earnings + last 4 quarters EPS surprise > 0%. That's exactly met. +5 for guidance raise. Total 15.)\n- Mispricing: 0 pts (Fwd P/E 26x, EV/EBITDA 34x, FCF yield 2.6% - no discount)\n- Quality: 5 pts (net debt/EBITDA -10.7, so net cash. That's 5 pts. ROIC and gross margin not provided, so 0 for those. Total 5.)\n- Technical: 3 pts (above 50DMA and 200DMA). RSI 74.4 (overbought, not 40-65). MACD no cross. 12-1 momentum not given. Total 3.\nTotal Score: 0 + 0 + 15 + 0 + 5 + 3 = 23.\nAnti-signals: `low_liquidity`, `pump_signals`. The rubric says: \"Avg daily volume < $5M (liquidity gate)\" and \"Pump-and-dump signals (sudden volume + chat-room mentions)\". The dossier explicitly lists these as anti_signals_present. This forces a skip regardless of score.\nAlso, the score is 23, which is < 45. Threshold says skip.\nReason: Score is low (23/100) due to lack of smart money flow, full valuation, and overbought technicals. Additionally, anti-signal gates for low liquidity and pump/dump signals mandate a skip. The market has already priced in the ASCO catalysts, leaving no asymmetric upside or income structure edge.\n\nLet's double check the score breakdown.\nA: 0\nB: 0\nC: 15 (10 for earnings + 4 beats, +5 for guidance raise)\nD: 0\nE: 5 (net cash / low debt)\nF: 3 (above 50/200 DMA)\nTotal: 23.\n\nWait, catalyst rubric:\n• 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0% -> Met.\n• 5 pts: recent guidance raise (last 90 days) -> Met.\nTotal C = 15.\n\nQuality rubric:\n• 5 pts: net debt / EBITDA ≤ 2x (or net cash) -> Met (-10.7).\nTotal E = 5.\n\nTechnical rubric:\n• 3 pts: above both 50DMA and 200DMA -> Met.\nTotal F = 3.\n\nSum = 23.\nAnti-signals present: low_liquidity, pump_signals.\nRule: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI will state that the anti-signals (liquidity and pump/dump flags) combined with the lack of valuation discount and overbought technicals make this a clear skip.\n\nOutput format:\n{\n  \"skip\": true,\n  \"score\": 23,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 15,\n    \"mispricing\": 0,\n    \"quality\": 5,\n    \"technical\": 3\n  },\n  \"reason\": \"Score of 23/100 reflects full valuation, overbought technicals, and zero smart-money conviction. Anti-signal gates for low liquidity and pump/dump patterns mandate a skip, and the recent ASCO catalysts are already fully priced in with no asymmetric upside or income structure edge.\"\n}\n\nCheck constraints:\n- \"ONLY ONE STRUCTURE TYPE.\" -> skip so irrelevant.\n- \"ALL NUMBERS must be drawn from the dossier or computable from it.\" -> Checked.\n- \"OUTPUT ONLY VALID JSON.\" -> Checked.\n- Date rules: not applicable for skip.\n- Thresholds: <45 skip.\n- Anti-signal gate: checked.\n\nEverything aligns. I will produce the JSON. \nOne minor thing: The prompt says \"Penalty: −10 pts if material insider SELLING > BUYING in dollars\". The dossier says \"Zero true discretionary open-market purchases... all 30 recent Form 4 filings are routine — RSU vesting... tax-withholding sells\". So selling > buying, but it's routine. I'll stick with 0 for smart money.\nScore breakdown sums to 23.\nReason is concise.\nReady. \nOutput matches exactly. \nProceeds. \nSelf-Correction/Refinement during thought: \nWait, the prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" I will mention that in the reason. \nAlso, the score is 23. \nI will generate the JSON exactly as requested.\nNo extra text.\nDone. \nOutput Generation. \n```json\n{\n  \"skip\": true,\n  \"score\": 23,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 15,\n    \"mispricing\": 0,\n    \"quality\": 5,\n    \"technical\": 3\n  },\n  \"reason\": \"Score of 23/100 reflects full valuation, overbought technicals, and zero smart-money conviction. Anti-signal gates for low liquidity and pump/dump patterns mandate a skip, and the recent ASCO catalysts are already fully priced in with no asymmetric upside or income structure edge.\"\n}\n```\nMatches requirements. Proceeds. \nAll constraints met. Output matches exactly. \nFinal Check of the prompt: \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\" -> I will output raw JSON without markdown code blocks as requested. Wait, the prompt says \"no markdown fences\" explicitly. I will just output the raw JSON string.\nDone. \nProceeds. \n[Output Generation] -> *Self-Correction/Note during generation*: The prompt says \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\" I will strictly follow that.\nScore breakdown: smart_money: 0, options_flow: 0, catalyst: 15, mispricing: 0, quality: 5, technical: 3. Sum = 23.\nReason covers anti-signals and valuation.\nReady. \nOutput matches. \nProceeds. \n[Done]\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 23,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 15,\n    \"mispricing\": 0,\n    \"quality\": 5,\n    \"technical\": 3\n  },\n  \"reason\": \"Score of 23/100 reflects full valuation, overbought technicals, and zero smart-money conviction. Anti-signal gates for low liquidity and pump/dump patterns mandate a skip, and the recent ASCO catalysts are already fully priced in with no asymmetric upside or income structure edge.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 23,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 15,\n    \"mispricing\": 0,\n    \"quality\": 5,\n    \"technical\": 3\n  },\n  \"reason\": \"Score of 23/100 reflects full valuation, overbought technicals, and zero smart-money conviction. Anti-signal gates for low liquidity and pump/dump patterns mandate a skip, and the recent ASCO catalysts are already fully priced in with no asymmetric upside or income structure edge.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 23,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 15,\n    \"mispricing\": 0,\n    \"quality\": 5,\n    \"technical\": 3\n  },\n  \"reason\": \"Score of 23/100 reflects full valuation, overbought technicals, and zero smart-money conviction. Anti-signal gates for low liquidity and pump/dump patterns mandate a skip, and the recent ASCO catalysts are already fully priced in with no asymmetric upside or income structure edge.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 47648,
  "stop_reason": "stop",
  "completed_at": "2026-06-05T02:01:57.591Z"
}